Which statement about desmopressin acetate (DDAVP) is true?

Prepare for the Endocrine Disorder Test. Engage with multiple choice questions with hints and explanations, ensuring a thorough understanding of endocrine system concepts. Excel in your exam with confidence!

Multiple Choice

Which statement about desmopressin acetate (DDAVP) is true?

Explanation:
Desmopressin acetate acts as a synthetic analogue of antidiuretic hormone, so it directly replaces what’s deficient in central diabetes insipidus. In central DI, ADH is lacking, and DDAVP binds to renal V2 receptors in the collecting ducts, prompting insertion of aquaporin-2 channels. This increases water reabsorption, concentrates the urine, and reduces urine output. Because the kidneys still respond to ADH, this treatment effectively helps control the symptoms of central DI. It is not a permanent cure—DI often requires ongoing management and may have different underlying causes. Desmopressin can be given by several routes, including intranasal and oral forms, but the key point for this question is that it is used to manage central diabetes insipidus. In someone with hyponatremia, there’s a risk that DDAVP could worsen water retention and lower sodium further, so any use must be cautious, but that caveat doesn’t override its role in treating central DI.

Desmopressin acetate acts as a synthetic analogue of antidiuretic hormone, so it directly replaces what’s deficient in central diabetes insipidus. In central DI, ADH is lacking, and DDAVP binds to renal V2 receptors in the collecting ducts, prompting insertion of aquaporin-2 channels. This increases water reabsorption, concentrates the urine, and reduces urine output. Because the kidneys still respond to ADH, this treatment effectively helps control the symptoms of central DI. It is not a permanent cure—DI often requires ongoing management and may have different underlying causes. Desmopressin can be given by several routes, including intranasal and oral forms, but the key point for this question is that it is used to manage central diabetes insipidus. In someone with hyponatremia, there’s a risk that DDAVP could worsen water retention and lower sodium further, so any use must be cautious, but that caveat doesn’t override its role in treating central DI.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy